Investigation on the correlation and clinical significance of serum mammaglobin and breast cancer

doi:10.3969/j.issn.1673-8640.2014.01.015

Abstract

Abstract: Objective To investigate the correlations of serum human mammaglobin(hMAM)levels with the early diagnosis of breast cancer and cancer micro-metastasis and their clinical significance. Methods By enzyme-linked immunosorbent assay(ELISA), the serum hMAM levels of 68 patients with breast cancer, 40 patients with other cancers (10 patients with prostate cancer, 10 patients with gastric cancer, 10 patients with ovarian cancer and 10 patients with colorectal cancer), 35 patients with benign breast disease and 40 healthy females (control group) were determined and analyzed comparatively. The 68 patients with breast cancer were classified according to TNM stage, whether existed the estrogen receptor (ER) expression, axillary lymph node metastasis and menopause. The cut-off value of serum hMAM in patients with breast cancer was determined by receiver operating characteristic (ROC) curve. Results The area under ROC curve of serum hMAM was 0.825, and the reliability in the diagnosis of breast cancer was 82.5% [95% confidence interval (CI): 72.6%-92.4%]. When the cut-off value for hMAM was 8.43 ng/mL, the sensitivity and specificity were 76.5% and 82.9%, respectively. Serum hMAM levels and positive rate in breast cancer group were significantly higher than those in benign breast disease group, other cancer group and control group (P<0.05). The difference among benign breast disease group, other cancer group and control group was not statistically significant (P>0.05). The positive rates of serum hMAM of Ⅲ and Ⅳ breast cancer patients (55% and 75%) were significantly higher than those of Ⅰ and Ⅱ patients (25% and 40%, P<0.05), but hMAM levels had no difference (P>0.05). The positive rate of serum hMAM in breast cancer patients with axillary lymph node metastasis (88%) was significantly higher than those without metastasis (30%, P<0.05), but hMAM levels had no difference (P>0.05). Regardless of whether existed ER expression, proto-oncogene C-erb-2 expression and menopause, serum hMAM levels and positive rate of patients with breast cancer had no difference (P>0.05). Results The hMAM expression is related with the clinical stage and axillary lymph node metastasis of breast cancer. The determination of serum hMAM level is helpful to improve the early diagnosis of breast cancer and early detection of cancer micro-metastasis.

Key words: Human mammaglobin, Breast cancer, Micro-metastasis

CLC Number:

R446.1

YANG Chao, KANG Wei, LI Jianhua, YOU Tao, WANG Yongfang.. Investigation on the correlation and clinical significance of serum mammaglobin and breast cancer[J]. , 2014, 29(1): 61-64.

References

[1] Waston MA, Fleming TP. Mammaglobin a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer[J]. Cancer Res, 1996, 56(4): 860-865.
[2] Li G, Zhang J, Jin K, et al. Human mammaglobin:a superior marker for reverse-transcriptase PCR in detecting circulating tumor cells in breast cancer patients[J]. Biomark Med, 2011, 5(2): 249-260.
[3] 吕晓娟, 黄焰, 张贺秋, 等. 乳腺珠蛋白在乳腺癌、良性病变及正常乳腺组织中的表达及其临床意义[J]. 军事医学, 2012, 36(2):137-140.
[4] Rehman F, Nagi AH, Hussain M. Immunohisto-chemical expression and correlation of mammaglobin with the grading system of breast carcinoma[J]. Indian J Pathol Microbiol, 2010, 53(4): 619-623.
[5] 吕赛平, 邹学森. 人乳腺珠蛋白检测在乳腺癌诊断中的临床应用进展[J]. 实用癌症杂志, 2010, 25(3):321-322.
[6] 顾敏, 吴敏, 党胜春. 乳腺癌患者外周血hMAM mRNA的表达与C-erbB-2、ER、PR及p53的相关性[J].山东医药, 2009, 49(44):48-49.
[7] Span PN, Van Laarhoven HW, Sweep FC. Mamma-globin RT-qPCR for breast cancer metastasis detection in sentinel lymph nodes[J]. Cancer Sci, 2010, 101(11): 2501.
[8] 周伟, 黄焰.乳腺珠蛋白研究及应用进展[J]. 生物技术通讯, 2011, 22(4):572-574.
[9] Fanger GR, Houghton RL, Retter MW, et al. Detection of mammaglobin in the sera of patients with breast cancer[J]. Tumour Biol, 2002, 23(4): 212-221.
[10] Berustein JL, Godbold JH, Raptis G, et al. Identification of mammaglobin as a novel serum marker for breast cancer[J]. Clin Cancer Res, 2005, 11(18): 6528-6535.
[11] Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer[J]. Clin Biochem, 2004, 37(4): 249-257.
[12] Smith RA, Cokkinides V, Eyre HJ, et al. American cancer society guidelines for the early detection of cancer, 2003[J]. CA Cancer J Clin, 2003, 53 (1): 27-43.
[13] Van der Auwera I, Peeters D, Benoy IH, et al. Circulating tumour cell detection:a direct comparison between the cell search system, the Adna Test and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer[J]. Br J Cancer, 2010, 102(2): 276-284.

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578.
[3]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429.
[4]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[5]	LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147.
[6]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[7]	WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820.
[8]	YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517.
[9]	YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348.
[10]	ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40.
[11]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[12]	YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329.
[13]	LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158.
[14]	JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486.
[15]	MEI Zhaoling, ZHOU Wenhui, FENG Jing. The Progress of Exosomes Application in Diagnosis and Treatmeat of breast cancer [J]. Laboratory Medicine, 2020, 35(12): 1203-1206.